http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210134242-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01L2200-0663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2527-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2563-107 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-701 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6844 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 |
| filingDate | 2021-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210134242-A |
| titleOfInvention | System for identifying severe acute respiratory syndrome corona virus 2 (sars-cov-2) ribonucleic acid (rna) |
| abstract | A system for detecting the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a biological sample includes a sampling device, a dissolution chamber, a NASBA fluid network and an analytical instrument. The sampling device is configured to contain a sample comprising a pathogen target sequence for SARS-CoV-2. The dissolution chamber is configured to be in fluid communication with the sampling device for receiving a sample. The dissolution chamber is configured to dissolve the sample into a lysate. A NASBA fluid network is configured in fluid communication with the dissolution chamber to receive a lysate. The NASBA fluid network includes enzymes, forward primers and reverse primers for amplifying a predetermined gene sequence from a pathogen target sequence contained in the lysate. The forward primer has an oligonucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13 and SEQ ID NO: 17. The reverse primer has an oligonucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14 and SEQ ID NO: 18. The molecular beacon is configured to attach to a pathogen target sequence. The beacon has an oligonucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15 and SEQ ID NO: 19 and a fluorophore. The assay instrument is configured to excite the molecular beacon when the molecular beacon is attached to the pathogen target sequence to signal the presence of the pathogen target sequence. |
| priorityDate | 2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.